Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has multiple ...

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S ...

Merck has opened a $1 billion, 225,000-square-foot facility at its Durham campus dedicated to vaccine manufacturing, the drug ...

According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent ...

Given the lack of solid evidence on a causal relationship between Gardasil and the two conditions, Merck didn’t possess the authority to simply change the vaccine’s label of its own accord ...

According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a ...

Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and ...

2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to vaccine ...

while Pneumovax 23 (pneumococcal vaccine polyvalent) vaccine sales declined 12% to $74 million. Sales of Vaxneuvance, Merck’s pneumococcal 15-valent conjugate vaccine, were $161 million ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of ...